Home Newsfeeds Barclays Maintains Equal-Weight on AbbVie, Lowers Price Target to $155

Barclays Maintains Equal-Weight on AbbVie, Lowers Price Target to $155

Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Equal-Weight and lowers the price target from $160 to $155.

byBenzinga Newsdesk

October 31, 2022

1 minute read

Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Equal-Weight and lowers the price target from $160 to $155.

Analyst Ratings

Expert Ratings for SI-BONE

By Benzinga Insights

November 8, 11:23 AM

Analysts have provided the following ratings for SI-BONE (NASDAQ:SIBN) within the last quarter:

SIBN

Putin’s Government To Launch Gold-Backed Stablecoin With Iran: Report

By Mehab Qureshi

January 16, 10:19 PM

The Central Bank of Iran is reportedly collaborating with the Russian administration to jointly launch a new stablecoin that is backed by gold.

$USDT

Bitcoin, Ethereum, Dogecoin Slide Amid Credit Suisse Worries: Analyst Eyes ‘Textbook Perfect’ Apex Crypto Move To $100K

By Mehab Qureshi

March 15, 10:28 PM

Major coins traded in the red on Wednesday evening as investors reacted to the possibility of a European banking crisis arising from worries surrounding Credit Suisse Group

$DOGE

Lilly Receives U.S. FDA Fast Track Designation For Tirzepatide For The Treatment Of Adults With Obesity, Or Overweight With Weight-related Comorbidities

By Benzinga Newsdesk

October 6, 6:45 AM

Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or

LLY

Barclays Maintains Equal-Weight on AbbVie, Lowers Price Target to $155

Related Posts

Expert Ratings for SI-BONE

Putin’s Government To Launch Gold-Backed Stablecoin With Iran: Report

Bitcoin, Ethereum, Dogecoin Slide Amid Credit Suisse Worries: Analyst Eyes ‘Textbook Perfect’ Apex Crypto Move To $100K

Lilly Receives U.S. FDA Fast Track Designation For Tirzepatide For The Treatment Of Adults With Obesity, Or Overweight With Weight-related Comorbidities